Literature DB >> 8461978

HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates.

J M Hill1, R F Mervis, R Avidor, T W Moody, D E Brenneman.   

Abstract

Cognitive and motor impairment are common symptoms among patients infected with the human immunodeficiency virus (HIV), including children who suffer neurological deficits and are frequently developmentally impaired. The HIV envelope protein, gp120, which has been shown to be toxic to neurons in culture, is shed in abundance by infected cells, and thus may play a significant role in the neuropathology of AIDS. To test this possible mechanism, neonatal rats were injected systemically with purified gp120 and the following consequences were observed: (1) radiolabeled gp120 and toxic fragments thereof were recovered in brain homogenates; (2) dystrophic changes were produced in pyramidal neurons of cerebral cortex; (3) retardation was evident in developmental milestones associated with complex motor behaviors. In parallel studies, co-treatment with peptide T, a gp120-derived peptide having a pentapeptide sequence homologous with vasoactive intestinal peptide, prevented or attenuated the morphological damage and behavioral delays associated with gp120 treatment. These studies suggest that gp120 and gp120-derived toxic fragments may contribute to the neurological and neuropsychiatric impairment related to HIV infection, and that peptide T appears to be effective in preventing gp120-associated neurotoxicity in developing rodents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461978     DOI: 10.1016/0006-8993(93)91241-j

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  31 in total

Review 1.  In vitro and animal models of human immunodeficiency virus infection of the central nervous system.

Authors:  Chadd E Nesbit; Stanley A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 2.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

3.  Neonatal intrahippocampal gp120 injection: an examination early in development.

Authors:  Sylvia Fitting; Rosemarie M Booze; Charles F Mactutus
Journal:  Neurotoxicology       Date:  2006-07-31       Impact factor: 4.294

Review 4.  In vitro methods in the study of viral and prion permeability across the blood-brain barrier.

Authors:  Ryota Nakaoke; William A Banks
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

5.  Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment.

Authors:  Karl Goodkin; Benedetto Vitiello; William D Lyman; Deshratn Asthana; J Hampton Atkinson; Peter N R Heseltine; Rebeca Molina; Wenli Zheng; Imad Khamis; Frances L Wilkie; Paul Shapshak
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

6.  A femtomolar-acting neuroprotective peptide.

Authors:  D E Brenneman; I Gozes
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

7.  HIV gp120 inhibits the somatotropic axis: a possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting.

Authors:  S E Mulroney; K J McDonnell; C B Pert; M R Ruff; Z Resch; W K Samson; M D Lumpkin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 8.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

9.  Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia.

Authors:  I P Everall; J D Glass; J McArthur; E Spargo; P Lantos
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Neonatal hippocampal Tat injections: developmental effects on prepulse inhibition (PPI) of the auditory startle response.

Authors:  Sylvia Fitting; Rosemarie M Booze; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2006-03-13       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.